In-Silico Investigation of PAI-1 Structural Changes in Active Forms of The Protein
Archives of Advances in Biosciences,
Vol. 15 No. 1 (2024),
24 Bahman 2024
,
Page 1-9
https://doi.org/10.22037/aab.v15i1.45593
Abstract
Introduction: Plasminogen activator inhibitor-1 (PAI-1) is a protein that plays an important role in regulating the fibrinolytic system, which is responsible for breaking down blood clots. Dysregulation of PAI-1 has been implicated in various diseases, including thrombosis, atherosclerosis, and cancer. Hence, expanding our knowledge of the PAI-1 structure is important for developing new therapies for these diseases. In this study, we aimed to compare the active form of Neovison and Human PAI-1 structures to rationalize pharmaceutical inhibitors in future studies.
Materials and Methods: The Neovison PAI-1 protein model was generated using MODELLER, and the validity of the constructed model was confirmed through various validation servers. Subsequent analyses, including root mean square deviation (RMSD), root mean square fluctuation (RMSF), and solvent-accessible surface area (SASA), were performed over a 40 ns molecular dynamics (MD) simulation.
Results: The data analysis of MD simulations and superimposed structures revealed that the stability of the Neovison PAI-1 protein is slightly higher than that of the Human PAI-1 protein; however, this difference is negligible. These findings were corroborated by the average RMSD, RMSF, and SASA plot values.
Conclusion: These results suggest a new landscape for the design of inhibitors and enable a more accurate identification of the PAI-1 structure.
- Plasminogen activator inhibitor 1
- Molecular Dynamic Simulation
- Homology Modeling
How to Cite
References
Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-8.
[DOI:10.1038/nature06797] [PMID] [PMCID]
Chandler WL. The human fibrinolytic system. Critical reviews in oncology/hematology. 1996;24(1):27-45.
[DOI:10.1016/1040-8428(96)00206-5] [PMID]
Van den Burg P, Hospers J, Mosterd W, Bouma B, Huisveld I. Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products. Journal of Applied Physiology. 2000;88(5):1558-64.
[DOI:10.1152/jappl.2000.88.5.1558] [PMID]
Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. 1984. [DOI:10.1182/blood.V64.4.907.907] [PMID]
Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene. 2004;23(41):6986-90.
[DOI:10.1038/sj.onc.1207859] [PMID]
Khan SS, Shah SJ, Klyachko E, Baldridge AS, Eren M, Place AT, et al. A null mutation in SERPINE1 protects against biological aging in humans. Science advances. 2017;3(11):eaao1617.
[DOI:10.1126/sciadv.aao1617] [PMID]
Liu R-M. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxidants & redox signaling. 2008;10(2):303-20.
[DOI:10.1089/ars.2007.1903] [PMID] [PMCID]
Rabieian R, Boshtam M, Zareei M, Kouhpayeh S, Masoudifar A, Mirzaei H. Plasminogen activator inhibitor type‐1 as a regulator of fibrosis. Journal of cellular biochemistry. 2018;119(1):17-27.
[DOI:10.1002/jcb.26146] [PMID]
Yamamoto K, Takeshita K, Shimokawa T, Yi H, Isobe K-i, Loskutoff DJ, et al. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proceedings of the National Academy of Sciences. 2002;99(2):890-5.
[DOI:10.1073/pnas.022608799] [PMID] [PMCID]
Gettins PG, Olson ST. Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Biochemical Journal. 2016;473(15):2273-93. [DOI:10.1042/BCJ20160014] [PMID] [PMCID]
Wind T, Hansen M, Jensen JK, Andreasen PA. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. 2002.
[DOI:10.1515/BC.2002.003] [PMID]
Declerck PJ, Alessi M-C, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. 1988. [DOI:10.1182/blood.V71.1.220.220] [PMID]
Hekman C, Loskutoff D. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. Journal of biological chemistry. 1985;260(21):11581-7. [DOI:10.1016/S0021-9258(17)39071-3] [PMID]
Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, et al. Structural basis of latency in plasminogen activator inhibitor-1. Nature. 1992;355(6357):270-3.
[DOI:10.1038/355270a0] [PMID]
Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure. 1999;7(2):111-8.
[DOI:10.1016/S0969-2126(99)80018-5] [PMID]
Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. Journal of Biological Chemistry.
;269(21):15223-8.
[DOI:10.1016/S0021-9258(17)36595-X] [PMID]
Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin: implications for the regulation of pericellular proteolysis. Journal of Biological Chemistry. 1997;272(12):7676-80. [DOI:10.1074/jbc.272.12.7676] [PMID]
Seiffert D, Loskutoff D. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. Journal of Biological Chemistry. 1991;266(5):2824-30.
[DOI:10.1016/S0021-9258(18)49921-8] [PMID]
Dewilde M, Van De Craen B, Compernolle G, Madsen JB, Strelkov S, Gils A, et al. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. Journal of structural biology. 2010;171(1):95-101. [DOI:10.1016/j.jsb.2010.03.006] [PMID]
Sillen M, Weeks SD, Strelkov SV, Declerck PJ. Structural insights into the mechanism of a nanobody that stabilizes PAI-1 and modulates its activity. International Journal of Molecular Sciences. 2020;21(16):5859.
[DOI:10.3390/ijms21165859] [PMID]
Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005;26(16):1701-18. [DOI:10.1002/jcc.20291] [PMID]
Abraham MJ, Murtola T, Schulz R. Pá ll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015; 1–2: 19–25.
[DOI:10.1016/j.softx.2015.06.001]
Salsbury Jr FR. Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Current opinion in pharmacology. 2010;10(6):738-44. [DOI:10.1016/j.coph.2010.09.016]
[PMID] [PMCID]
Hantington J. vol. 9, issue Suppl. 1. J Thromb Haemost. 2011:26-34. [DOI:10.1111/jth.12979]
Vousden KA, Lundqvist T, Popovic B, Naiman B, Carruthers AM, Newton P, et al. Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1. Scientific reports. 2019;9(1):1-12. [DOI:10.1038/s41598-019-38842-x]
[PMID] [PMCID]
Subramanian U, Sivapunniyam A, Pudukadu Munusamy A, Sundaram R. An in silico approach towards the prediction of druglikeness properties of inhibitors of plasminogen activator inhibitor1. Advances in Bioinformatics. 2014;2014(1):385418. [DOI:10.1155/2014/385418] [PMID] [PMCID]
Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006–present). Expert opinion on therapeutic patents. 2013;23(7):801-15. [DOI:10.1517/13543776.2013.782393] [PMID]
Nar H, Bauer M, Stassen J-M, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. Journal of molecular biology. 2000;297(3):683-95. [DOI:10.1006/jmbi.2000.3604] [PMID]
Stout TJ, Graham H, Buckley DI, Matthews DJ. Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry. 2000;39(29):8460-9. [DOI:10.1021/bi000290w][PMID]
Sillen M, Miyata T, Vaughan DE, Strelkov SV, Declerck PJ. Structural insight into the two-step mechanism of PAI-1 inhibition by small molecule TM5484. International journal of molecular sciences. 2021;22(3):1482.
[DOI:10.3390/ijms22031482] [PMID] [PMCID]
- Abstract Viewed: 257 times
- pdf Downloaded: 104 times